Background: Allergic asthma is a prevalent inflammatory disease of the airways caused by dysregulated immune balance in the lungs with incompletely understood pathogenesis. The recently identified type 2 innate lymphoid cells (ILC2s) play significant roles in the pathogenesis of asthma. Although ILC2-activating factors have been identified, the mechanisms that suppress ILC2s remain largely unknown. Plasmacytoid dendritic cells (pDCs) are important in antiviral immunity and in maintaining tolerance to inert antigens. Objective: We sought to address the role of pDCs in regulating ILC2 function and ILC2-mediated airway hyperreactivity (AHR) and lung inflammation. Methods: We used several murine models, including BDCA-2-diphtheria toxin receptor (DTR) transgenic and IFN-a receptor 1-deficient mice, as well as purified primary ILC2s, to reach our objective. We extended and validated our findings to human ILC2s. Results: We show that activation of pDCs through Toll-like receptor 7/8 suppresses ILC2-mediated AHR and airway inflammation and that depletion of pDCs reverses this suppression. We further show that pDCs suppress cytokine production and the proliferation rate while increasing the apoptosis rate of ILC2s through IFN-a production. Transcriptomic analysis of both human and murine ILC2s confirms the activation of regulatory pathways in ILC2s by IFN-a. Conclusion: Activation of pDCs alleviates AHR and airway inflammation by suppressing ILC2 function and survival. Our Allergic asthma is a chronic inflammatory disease of the airways caused by dysregulated immune responses to inhaled antigens. Asthma currently affects more that 24 million persons in the United States, with increasing prevalence. 1 There is an unmet clinical need for effective therapies that intercept asthma pathogenesis and prevent disease progression. Developing such therapies is hampered by the lack of a complete understanding of asthma pathogenesis. The allergic response underlying asthma is the outcome of the dysregulated balance between deleterious immune response and regulatory mechanisms. T H 2 cells and their associated cytokines, IL-4, IL-5, and IL-13, were initially identified as the main components of the deleterious immune response in the pathogenesis of allergic diseases and asthma. 2 Recently, type 2 innate lymphoid cells (ILC2s) have been identified as significant producers of type 2 cytokines in mucosal tissues, especially in acute stages of allergic and antihelminth responses. 3, 4 In contrast to type 2 cytokine-producing cells, regulatory T (Treg) cells and plasmacytoid dendritic cells (pDCs) have been shown to play significant roles in controlling and suppressing the deleterious allergic immune response.
pDCs play multifaceted roles in host defense by producing type I interferon and IL-6 and in immune regulation by inducing Treg cells. 5, 6 It has been shown that pDCs play an indispensable role in the pulmonary immune response while maintaining respiratory tolerance to harmless inhaled antigens. 7 Recognition of viral or self-nucleic acids through Toll-like receptor (TLR) 7 and TLR9 activates pDCs to produce high amounts of type I interferon. [8] [9] [10] For instance, HIV activates human pDCs through TLR7 and leads to production of type I interferon by these cells. 11 We and others have shown that TLR7/TLR9-activated pDCs contribute to immune regulation by inducing Treg cells and causing negative selection of antigen-specific thymocytes. [12] [13] [14] Interestingly, there is evidence suggesting that activated pDCs promote HIV-induced depletion of type 3 innate lymphoid cells in a humanized murine model. 15 Whether pDCs can directly regulate and suppress the proliferation/apoptosis rate of ILC2s and their cytokine production has not been reported to date.
ILC2s reside at mucosal surfaces, including the lungs, and play a significant role in antihelminth immune responses, as well as in sustaining eosinophils in adipose tissues by producing the type 2 cytokines IL-5 and IL-13. 3, 16 ILC2s also play an important role in the pathogenesis of allergic diseases and asthma. There is evidence indicating that ILC2s are critical for initiation of the T H 2 response. [17] [18] [19] The mechanisms of activation of ILC2s have been the subject of extensive research. ILC2s lack antigen receptors and are activated by epitheliumderived cytokines, such as IL-33, IL-25, and thymic stromal lymphopoietin. There is evidence suggesting that IL-33 is more potent than IL-25 in activating ILC2s. 20 On activation, ILC2s proliferate and produce abundant amounts of IL-5, IL-13, and IL-9. The biological processes that regulate the proliferation, apoptosis, and cytokine production of ILC2s remain unidentified.
In the current study we investigated the role of pDCs in regulating the function and survival of ILC2s in the context of allergic pulmonary inflammation. Using BDCA-2-diphtheria toxin receptor (DTR) transgenic mice, we specifically depleted pDCs and found evidence that pDCs restrain the cytokine production and survival of ILC2s. We identified the production of IFN-a as the main mechanism of pDC-mediated regulation of ILC2s. Moreover, we observed similar findings in human ILC2s. This study sheds new light on the underlying mechanisms of immune regulation by identifying the pDC-IFN-a axis as a novel pathway in regulating ILC2s in patients with pulmonary inflammation.
METHODS Mice
BALB/cByJ, recombination-activating gene 2 (Rag2) 2/2 , and BDCA2-DTR mice were purchased from the Jackson Laboratory (Bar Harbor, Me) and bred in our animal facility at the University of Southern California. IFN-a receptor 1 (Ifnar) 2/2 and C57BL/6J mice were purchased from the Jackson Laboratory and used directly in our experiments. We used 5-to 8-week-old age-matched female mice in our studies. All the described studies were approved by the Institutional Animal Care and Use Committee of the University of Southern California or Janssen Research & Development.
In vivo procedures and measurement of lung function
In the experiments described in Figs 1-5, we administrated the indicated dose of R848 (InvivoGen, San Diego, Calif) and Alternaria alternata (Greer Laboratories, Lenoir, NC) intranasally. Lung function was evaluated, as described previously. 21, 22 For further details, see the Methods section in this article's Online Repository at www.jacionline.org.
Collection of bronchoalveolar lavage fluid and lung histology
Bronchoalveolar lavage (BAL) was performed after evaluation of lung function in euthanized mice, as we described previously. 21, 23 For details, please refer to the Methods section in this article's Online Repository. After BAL, we took lung samples, fixed them in paraformaldehyde 4%, and created lung histology slides, as described previously. 15 Images of hematoxylin and eosin-stained tissue slides were acquired with a KeyenceBZ-9000 microscope (Keyence, Itasca, Ill). Histologic images were analyzed with the BZ-II Image Analysis Application (Keyence).
Cell sorting and flow cytometry
For a detailed description of flow cytometry reagents, see the Methods section in this article's Online Repository. For sorting murine pDCs, we first enriched the pDCs with the Plasmacytoid Dendritic Cell Isolation Kit and AutoMACSpro (Miltenyi Biotec, San Diego, Calif), according to the manufacturer's instructions. The pDC-enriched fraction and ILC2s were then purified by using fluorescence-activated cell sorting (FACS), as described in the Methods section in this article's Online Repository.
RNA sequencing and data analysis
Sequencing library generation. Human and murine ILC2s were purified as described above and cultured in the presence of IL-2, IL-7, and IL-33 (20 ng/mL each) and in the presence or absence of recombinant IFN-a for 9 hours. Total RNA was extracted from purified ILC2s, and the sequencing library was generated and data were analyzed, as described in the Methods section in this article's Online Repository.
Statistical analysis
We repeated each experiment at least 2 times (n 5 3-5 mice per group in each experiment), and data are representative of at least 2 independent experiments. Lung function data were analyzed by using repeated measurements with the general linear model. For comparing 2 groups, we used a Student t test confirmed by using a Mann-Whitney U test. For multigroup comparisons, we used 1-way ANOVA with the Bonferroni post hoc test. Data were analyzed with GraphPad Prism software (GraphPad Software, La Jolla, Calif). A P value of .05 or less was considered statistically significant.
RESULTS

Activation of pDCs suppresses ILC2-driven airway hyperreactivity and inflammation
We examined the effects of pDC activation on ILC2-derived airway hyperreactivity (AHR) using a clinically relevant allergen, Alternaria alternata extract (50 mg per mouse), on days 1 to 4 (Fig 1, A) . We and others have shown that A alternata activates ILC2s and causes AHR and eosinophilic inflammation in murine E, We purified pDCs and ILC2s from the spleens and lungs of WT mice, respectively. Purified pDCs were stimulated with R848 for 48 hours, and then purified ILC2s were cultured with the supernatant of pDCs culture in the presence or absence of anti-IFN-a blocking antibody for 48 hours, followed by evaluation of IL-5 and IL-13 in the supernatant. Bar graphs show the concentration of IL-5 (Fig 3, E) and IL-13 (Fig 3,  F) in the supernatant of culture of ILC2s with activated pDC supernatants. Data are shown as means 6 SEMs (n 5 3-4 each). *P < .05, **P < .01, and ***P < .005. models. 21, 24 To exclude the effects of adaptive immunity, we used Rag2 2/2 mice that lack mature B and T cells. To activate pDCs, we administered the intranasal TLR7/8 agonist R848 on day zero and 30 minutes before each A alternata administration (Fig 1, A) . R848 has been shown to directly activate pDCs. 25, 26 A alternata administration caused AHR, as shown by the significant increase in lung resistance at methacholine doses of 10 to 40 mg/mL (P < .005; Fig 1, B, solid compared with open circles). Administration of R848 significantly reduced A alternatainduced increase in lung resistance (P < .005; Fig 1, B , solid squares compared with solid circles). However, lung resistance after R848 administration is significantly higher in the A alternata-receiving than the PBS-receiving control group (P < .05; Fig 1, B) .
Administration of A alternata extract dramatically increased the number of eosinophils in BAL fluid compared to PBS (P < .005; Fig 1, C) . Similarly, the number of eosinophils in the BAL fluid of mice that received R848 before A alternata was significantly lower than in mice that received only PBS before A alternata administration (P < .005; Fig 1, C) . The total number of ILC2s in the lungs was significantly higher in the group that received PBS and A alternata compared with the control group that received PBS and PBS (P < .005; Fig 1, D) . The total number of ILC2s in the lungs of mice that received R848 before A alternata is significantly lower than in those that received PBS (P < .005; Fig 1, D) .
Lung histology shows a notable increase in the thickness of airway epithelium and inflammation around the airways in the mice that received PBS-A alternata (Fig 1, E) . Mice that received R848-A alternata show diminished lung inflammation and thickness of airway epithelium similar to those of mice receiving PBS-PBS and R848-PBS. These results indicate that administration of R848 suppresses ILC2-driven AHR and inflammation, as well as ILC2 counts, presumably through activation of pDCs.
TLR7/8 agonist-induced suppression of ILC2s is mediated by pDCs
We next addressed the role of pDCs in regulating AHR and inflammation in a previously established murine model of ILC2-mediated asthma. 21, 24 In this model we induced AHR and airway inflammation by means of intranasal administration of IL-33 on 3 consecutive days and activated pDCs by means of intranasal administration of R848 on day zero and 30 minutes before each IL-33 administration (Fig 2, A) . To specifically address the role of pDCs, we used BDCA-2-DTR transgenic mice in which DTR is expressed under the transcriptional control of the BDCA-2 promoter. Because DTR is not expressed in murine cells, administration of diphtheria toxin (DT) specifically depletes pDCs in BDCA-2-DTR transgenic mice (see Fig E1 in this article's Online Repository at www.jacionline.org). 27 Evaluation of lung resistance and AHR, a cardinal feature of asthma, revealed that IL-33 administration resulted in a significant increase in lung resistance and AHR compared with PBS administration in pDC-undepleted mice (P < .05; Fig 2, B) . Activation of pDCs using R848 significantly reduced IL-33-induced lung resistance (P < .01; Fig 2, B) . The R848-mediated reduced lung resistance was reversed by depletion of pDCs, suggesting that the suppressive effects of R848 are mediated by pDCs. The level of lung resistance in mice that received IL-33 alone seems to be unaffected by the depletion of pDCs.
Analysis of eosinophil counts in BAL fluid showed that, as expected, the number of eosinophils in the BAL fluid of mice receiving IL-33 was significantly higher than that of mice receiving PBS (P < .05; Fig 2, C) . The number of eosinophils in the BAL fluid of mice receiving IL-33 treated with R848 was significantly lower than that of control mice receiving IL-33, suggesting that activation of pDCs by R848 suppresses IL-33-induced airway eosinophilia. This suppression is abrogated by depletion of pDCs, as evident by the lack of difference in the number of eosinophils between control mice receiving IL-33 and R848-treated mice that received DT.
To evaluate the effects of pDC activation on the function of ILC2s, we measured cytokine production by pulmonary ILC2s using an intracellular cytokine evaluation assay. Our results indicate that IL-33 administration significantly increased the number of IL-5 
IL-13
2 (double negative) ILC2s (Fig 2, D) . Because activated ILC2s produce both IL-5 and IL-13 and there is only a negligible number of solo IL-13 1 ILC2s in the lungs, this number seems to be unaffected by the tested conditions. Increased numbers of double-negative ILC2s in the IL-33-treated group compared with the control group might reflect the proliferation of the total population of ILC2s. R848 significantly reduces the number of double-negative, IL-5 1 , and double-positive ILC2s, and depletion of pDCs reverses the effects of R848 (Fig 2, D) . Analysis of lung histology showed findings similar to the AHR and BAL results (Fig 2, E) . Taken together, our data show that intranasal IL-33 administration leads to activation of ILC2s, AHR, and airway inflammation and that activation of pDCs by R848 suppresses IL-33-induced AHR and lung inflammation.
We further examined whether pDCs play a role in regulating ILC2s in response to clinically relevant allergens. We administered A alternata extract (50 mg per mouse) for 4 consecutive days (see Fig E2, of ILC2s in the lungs were evaluated 1 day after the last allergen exposure. Numbers of eosinophils in the BAL fluid and ILC2s in the lungs were significantly higher in mice receiving anti-mouse plasmacytoid dendritic cell antigen 1 than rat IgG 1 control mice (P < .01; see Fig E2, B and C) . These results suggest that pDCs restrain A alternata-induced activation of ILC2s.
R848 induces a rapid and early IFN-a production in the lungs
To identify the mechanisms of suppressive effects of pDCs, we investigated interferon production in the lungs in response to R848. We administered R848 intranasally to wild-type (WT) mice, followed by analysis of IFN-a, IFN-b, and IFN-g at several time points (Fig 3, A) . We observed a robust production of IFN-a but not IFN-b or IFN-g at 1 hour after R848 administration (Fig 3,  B) . To determine whether ILC2s directly respond to IFN-a, we evaluated the expression of IFNAR1 by freshly isolated and ex vivo-stimulated pulmonary ILC2s. We found that freshly isolated unstimulated pulmonary ILC2s readily express IFNAR1 (plotted as day 0; Fig 3, C and D) , and this expression has significantly and gradually increased over time after ex vivo stimulation with IL-33 (Fig 3, C and D) . Gating strategy and purity of ILC2s are shown in Fig E3 in this article' s Online Repository at www.jacionline.org. These results suggest that IFN-a production in response to R848 stimulation might directly affect the ILC2s.
To further reveal the mechanism of action of pDCs, we evaluated the production of IL-5 and IL-13 by purified WT ILC2s cultured in the presence of R848 in the presence or absence of pDC supernatant (Fig 3, E and F) . To examine the role of IFN-a in suppressive effects of pDCs, we used anti-IFN-a blocking antibody. We found that ex vivo stimulation of ILC2s with IL-33 produced similar amounts of IL-5 and IL-13, even in the presence or absence (data not shown) of R848, suggesting ILC2s do not respond to R848 when cultured alone (Fig 3, E  and F) . Culture of ILC2s with pDC supernatant significantly reduced the amount of IL-5 and IL-13 in the supernatant, and blocking IFN-a with anti-IFN-a antibody reversed the suppressive effects of pDC supernatants (Fig 3, E and F) . Taken together, our results show that pDCs rapidly produce high amounts of IFN-a, which in turn directly suppresses cytokine production by ILC2s.
Adoptive transfer of activated pDCs did not suppress lung inflammation in the absence of IFNAR1
Because we observed that the suppressive effects of pDCs are mediated by IFN-a in our in vitro experiments, we further investigated the role of IFN-a in the suppressive effects of pDCs on ILC2-mediated lung inflammation in vivo. We isolated pDCs from the spleens and lungs of WT mice preinoculated by FMS-like tyrosine kinase 3 ligand-producing melanoma cells. We showed previously that this approach enables us to acquire a high number of pDCs without affecting their phenotype.
14 As shown in Fig 4, A, we purified pDCs, and after ex vivo activation with R848 for 2 hours, cells were washed extensively with PBS. We then adoptively transferred the activated pDCs to WT or Ifnar 2/2 mice through the intratracheal route. We administered recombinant murine IL-33 to the host mice for 3 consecutive days, followed by evaluation of airway and lung inflammation (Fig 4, A) . IL-33 administration induced similar numbers of eosinophils in WT and Ifnar 2/2 mice that did not receive pDC transfer (Fig 4, B) . Importantly, pDC transfer significantly decreased the number of eosinophils in WT hosts but did not decrease the number in Ifnar 2/2 mice. There was a trend toward an increase in the number of eosinophils in Ifnar 2/2 mice that received the pDC transfer and the control mice; however, this difference was not statistically significant. Analysis of lung histopathology revealed the presence of inflammatory cells around the airways and a clear increase in the thickness of the epithelium (Fig 4, C) in WT and Ifnar 2/2 mice receiving IL-33 that did not receive pDC transfer. We observed that the presence of inflammatory cells and the thickness of epithelium are diminished in WT hosts of pDCs but not in Ifnar 2/2 hosts. These results suggest that the suppressive effects of pDCs on IL-33-induced ILC2-mediated airway and lung inflammation are mediated by IFN-a through IFNAR1 expression in non-pDCs.
IFN-a suppresses ILC2-mediated airway inflammation and AHR in vivo
We investigated further whether IFN-a is sufficient to suppress AHR and airway inflammation in vivo. To exclude the role of adaptive immunity in this process, we used Rag2 2/2 mice, which lack mature B and T cells. Similar to the aforementioned experiments, we administered IL-33 intranasally alone or in combination with IFN-a to Rag2 2/2 mice for 3 consecutive days and evaluated AHR and lung inflammation 1 day after the last intranasal administration. Our data show that IFN-a significantly reduces lung resistance and increases dynamic compliance (Fig 5, A and B) , Analysis of the BAL fluid contents shows that IFN-a significantly decreased the number of airway eosinophils as well (Fig 5, C) . Analysis of the lungs revealed that IL-33 treatment significantly increased the number of ILC2s in the lungs compared with PBS (P < .005; Fig 5, D) . The IFN-a-treated group shows a significantly lower number of ILC2s compared with the group that received only IL-33 (P < .005; Fig 5, D) . These data clearly indicate that intranasal IFN-a is sufficient to suppress ILC2-medated AHR and airway inflammation.
IFN-a inhibits proliferation and induces apoptosis in ILC2s
To investigate the molecular regulation of pDC-mediated suppression of ILC2s, we identified the transcriptomic profile of ILC2s using RNA sequencing (RNA-Seq) after culturing ILC2s in the presence or absence of IL-33 or IFN-a ex vivo for 9 hours. Heat maps shown in Fig 6, A, reflect the abundance of a list of depicted transcripts relative to each row. RNA-Seq data show that IFN-a increased expression of the proapoptotic genes Bak1, Casp8, and Apaf1 and decreased expression of Bax. IFN-a increased the abundance of genes that are involved in IFN-a signaling, such as Irf7, Stat1, and Stat2, which are known to be required for the antiproliferative activity of IFN-a, and decreased expression of Mtor, Pi3ka and Rac1. Moreover, although expression of Rorc was increased, expression of Id2, Notch1, Notch2, Stat6, and Zbtb16 was decreased in the presence of IFN-a. These data suggest that IFN-a enhances proapoptotic pathways while suppressing proliferation and stimulatory pathways.
To confirm the RNA-Seq findings, we next evaluated the rate of apoptosis and proliferation of ILC2s in the presence or absence of IFN-a. Similar to the protocol used in Fig 4, we intranasally administered IL-33 alone or in combination with IFN-a to the WT mice and evaluated the phenotype of ILC2s on day 4. We found that IFN-a increased the rate of apoptosis in the ILC2s (Fig 6, B) by increasing expression of the proapoptotic gene Casp8 in pulmonary ILC2s, confirming RNA-Seq data (Fig 6,  C) . We also found that IFN-a administration reduced the amount of a proliferation-associated protein, Ki-67, suggesting that IFN- ILC2s were isolated from the lungs and cultured in the presence of rmIL-2 or rmIL-7, in the presence or absence of rmIL-33, and in the presence or absence of recombinant murine IFN-a. After 9 hours, transcript abundance was evaluated by using next-generation mRNA sequencing. B, Representative dot plot of Annexin V binding and 7-aminoactinomycin (7-AAD) staining of lung ILC2s after intranasal administration of IL-33 and IFN-a on 3 consecutive days. C-E, Representative histograms of amount of caspase-8 (Fig 6, C) , Ki-67 (Fig 6, D) , and phosphorylated STAT5 (Fig 6, E) in lung ILC2s after IL-33 and IFN-a administration, as mentioned in Fig 6, B. F, Representative histogram of GATA-3 and T-bet in lung ILC2s after IL-33 and IFN-a administration, as described in Fig 6, B. G, Representative histograms of amount phosphorylated STAT1 in lung ILC2s. Data are representative of 2 individual experiments (n 5 3-4 each). Filled gray histograms represent isotype stain control. MFI, Median fluorescence intensity.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 3 a reduces the rate of proliferation of ILC2s (Fig 6, D) . Our data further show that IFN-a decreases the amount of phosphorylated signal transducer and activator of transcription (STAT) 5 (Fig 6,  E) . The amount of GATA-3 in pulmonary ILC2s seems to be unaffected by IFN-a (Fig 6, F) . Taken together, our data show that IFN-a induces apoptosis and hampers proliferation in ILC2s. Because STAT1 is downstream of IFN-a signaling, we evaluated the amount of phosphorylated STAT1 in ILC2s and found that IFN-a increases the amount of phosphorylated STAT1 in ILC2s (Fig 6, G) . We further investigated the role of STAT1 in IFN-a-mediated suppression of ILC2s in vivo by using Stat1 2/2 mice. WT or Stat1 2/2 mice received intranasal IL-33 (0.8 mg per mouse) alone or in combination with IFN-a (2 3 10 4 units per mouse) on days 1 to 3 (see Fig E4, A, in this article's Online Repository at www.jacionline.org). The number of eosinophils in BAL fluid is comparable in both strains of mice that received only IL-33 (see Fig E4, B) . The mice that received IFN-a show significantly lower number of eosinophils in the BAL fluid compared with those that received only IL-33 in both strains (P < .005; see Fig E4, B) . The number of eosinophils in BAL fluid of Stat1 2/2 mice that received IFN-a is significantly higher than in WT mice with similar treatment (P < .05; see Fig E4, B) . The total number of ILC2s in the lungs shows a pattern similar to eosinophils in BAL fluid, whereas there is no difference between WT and Stat1 2/2 mice in response to IL-33. The total number of ILC2s in IFN-a-treated Stat1 2/2 mice is significantly higher than in WT mice (P < .01; see Fig E4, C) . We evaluated cytokine production by lung ILC2s using intracellular staining and flow cytometry and found no significant difference between WT and Stat1 2/2 mice in response to IL-33 and IFN-a (see Fig E4, D) . These results suggest that the suppressive effects of IFN-a on ILC2s are partially mediated by STAT1.
Human pDCs suppress ILC2s and respond to IFN-a
To evaluate the translational aspects of our findings, we examined whether activated human pDCs can suppress human ILC2s. We purified human pDCs using magnetic isolation and ILC2s using flow cytometry from PBMCs of 5 healthy donors. pDCs were then cultured in the presence or absence of R848 (20 mg/mL), and innate lymphoid cells were cultured in the presence of recombinant human (rh) IL-2, rhIL-7, and rhIL-33 (20 ng/mL each) for 48 hours. Thereafter, supernatants of pDCs cultures were separated and added to the ILC2s and cultured for an additional 48 hours. Evaluation of cytokines in culture media showed that the supernatant of activated pDCs significantly suppresses IL-5 and IL-13 production by ILC2s (P < .01; Fig 7,  A and B) .
We next evaluated the expression of IFNAR1 in human ILC2s immediately after purification and after ex vivo stimulation with IL-33 for 24 and 72 hours. We found that freshly isolated human ILC2s readily express IFNAR1 at the steady state. Expression of IFNAR1 is significantly increased after 24 hours of culture in the presence of human recombinant IL-33 (10 ng/mL; Fig 7, C) . We further examined whether IFN-a affects the cytokine production of human ILC2s by culturing purified ILC2s in the presence of rhIL-33 and in the presence or absence of rhIL-33 and rhIFN-a for 48 hours. We found that, similar to murine ILC2s, the amount of IL-5 and IL-13 produced by human ILC2s is significantly reduced in the presence of IFN-a (Fig 7, D) .
We next compared the transcriptomic profile of ILC2s of 4 individual donors cultured in the presence or absence of IFN-a, as mentioned above, for 9 hours. Heat maps in Fig 6, D, show the abundance of a list of depicted genes relative to each gene (in rows). Columns indicate the individual donors. Similar to murine ILC2s, IFN-a increased the level of proapoptotic genes, such as CASP3, CASP7, and CASP8 while reducing expression of antiapoptotic genes, such as BCL2, in human ILC2s (Fig 7, F) . IFN-a reduced the level of transcription factors associated with ILC2s, such as BCL11B, ZBTB16, RORC, and ID2, suggesting that IFN-a might affect the plasticity and fate of human ILC2s (Fig 7, F) . IFN-a clearly increased the level of genes involved in the IFN-a signaling pathway, such as IEF7, IRF9, STAT1, and STAT2 (Fig 7, F) . Moreover, the level of expression of one of the hallmark genes of human ILC2s, CRTH2, is decreased in the presence of IFN-a. Overall, our data suggest that IFN-a potentiates the proapoptotic pathways in ILC2s and inhibits the stimulatory pathways in human ILC2s.
DISCUSSION
Studying the interplay between pDCs and ILC2s, we found that activation of pDCs with the TLR7/8 agonist R848 leads to suppression of ILC2-mediated airway inflammation and hyperreactivity through early production of copious amounts of IFN-a. Unlike previously reported regulatory effects of pDCs that are mediated by Treg cells, we provide the first evidence that activated pDCs directly suppress the proliferation, survival, and cytokine production of ILC2s.
Our findings demonstrate an important interplay between pDCs and ILC2s that controls the function and homeostasis of ILC2s in asthma pathogenesis. An increased number of ILC2s with augmented IL-5-and IL-13-producing capacity in response to IL-33 has been reported in peripheral blood of patients with allergic asthma compared with nonallergic subjects. 28 The ILC2-related genes IL33, IL1RL1 (IL-33 receptor) and PTGDR (CRTH2, a marker of human ILC2s) have been associated with asthma susceptibility in meta-analysis of genome-wide association studies of asthma. 29, 30 There is evidence indicating that the antiviral immune response is impaired in asthmatic patients. For instance, although TLR7 function has been reported to be impaired in adolescents with asthma, TLR7-triggered immune response induces a long-lasting suppression in experimental asthma. 31, 32 Interestingly, a clinical study found that low-dose IFN-a treatment was associated with a dramatic improvement in patients with corticosteroid-resistant asthma with an unidentified mechanism of action. 33 The direct effect of IFN-a on ILC2s, as we found, might offer a mechanism of action for the reported beneficial effects of IFN-a therapy in asthmatic patients.
We show that activation of pDCs leads to reduced numbers of ILC2s. These findings are in agreement with a recent report of pDC contribution to HIV-mediated depletion of type 3 innate lymphoid cells possibly through the FAS-FAS ligand pathway. 15 However, we found that IFN-a production by activated pDCs limits the proliferation rate and increases the apoptosis rate of ILC2s, which leads to the observed reduced number of ILC2s. We confirmed that IFN-a is sufficient in restraining the function and homeostasis of ILC2s. This finding is consistent with a previous report of suppressive effects of IFN-a, which uses the same receptor on ILC2s. 34 In addition, we characterized early gene modulations in human and murine ILC2s in response to IFNa signaling using transcriptome analysis and found that both intrinsic and extrinsic apoptosis regulatory genes were modulated by IFN-a to induce apoptosis. We provide evidence suggesting that suppressive effects of R848-activated pDCs on ILC2s are mediated by IFN-a rather than a direct effect of R848 on ILC2s. We observed that adoptively transferred pDCs suppressed ILC2-mediated pulmonary inflammation only in the WT hosts and not in Ifnar 2/2 hosts. Purified pDCs were stimulated with R848 in vitro, were extensively washed, and were adoptively transferred. Using this approach, we ensured that only transferred pDCs but not host ILC2s were exposed to R848. These findings clearly demonstrate that the suppressive effects of pDCs are mediated by IFN-a. Moreover, that pDC-derived IFN-a suppresses ILC2 numbers is shown by the results of experiments where purified ILC2s were cultured with activated pDC supernatant under several experiment conditions. R848 showed no effect on cytokine production when ILC2s are cultured alone. However, activation of pDCs by R848 leads to suppression of cytokine production by ILC2s in culture of ILC2s with activated pDC supernatant. Our findings are in accordance with recent reports that CASP8  BCL2  BID  CASP10  CASP3  CASP7  CYCS   BCL11B  ZBTB16  RORC  ID2  STAT6  TBX21  KLF4   IRS2  JAK1  RAC2  MAP3K5  STAT1  STAT2  IRF7  IRF9   PTGDR2  IFNAR1  IFNAR2  IL4R  IFNGR1  IFNGR2 A and B, Human pDCs and ILC2s were purified by using magnetic enrichments and flow cytometry, respectively. pDCs were cultured in the presence or absence of R848 (20 mg/mL) and ILC2s in the presence of rhIL-2, rhIL-7, and rhIL-33 (20 ng/mL each) for 48 hours (n 5 5). Then supernatants of pDCs were added to ILC2s and cultured for an additional 48 hours. Amounts of IL-5 (Fig 7, A) and IL-13 (Fig 7, B) in the supernatant were measured by using multiplex ELISA. C, Median fluorescence intensity (MFI) of IFNAR1 by human ILC2s. Isolated human ILC2s from the peripheral blood of healthy subjects were cultured in the presence of rhIL-2, rhIL-7, and rhIL-33. D and E, The amount of IL-5 (Fig 7, D) and IL-13 (Fig 7, E) , as measured by means of ELISA, in the supernatant of cultured human ILC2s after 48 hours. F, Heat maps show abundance of the indicated transcripts in purified human ILC2s cultured in vitro in the presence of rhIL-33 and in the presence or absence of IFN-a for 9 hours. Data are shown as means 6 SEMs (n 5 4-5). *P < .05.
type I and type II interferons have regulatory effects on ILC2s. [35] [36] [37] However, the source of IFN-a and a potential clinical implication of this regulatory pathway has not been reported. Here, in addition to the regulatory effects of IFN-a, we show that pDCs are a major source of this cytokine and that the TLR7 pathway could be used to regulate ILC2-induced AHR.
We used the TLR7 pathway to activate pDCs in our experiments because this stimulatory pathway has been shown to effectively activate pDCs and lead to IFN-a production by these cells. 25, 38 IFN-a has been shown to suppress expression of the GATA3 gene in T cells. 39 However, we found that expression of GATA-3 at the protein level is unaffected in response to IFN-a in ILC2s. We examined the mechanism of regulatory effects of IFN-a on ILC2s and found that IFN-a reduces the number of lung ILC2s though the induction of apoptosis and a reduced proliferation rate. We further show that the STAT1 and STAT5 pathways in ILC2s are affected by IFN-a, and using a knockout system, we show that the regulatory effects of IFN-a are partially mediated by STAT1.
Previous reports of the regulatory effects of pDCs mainly suggest that these effects are mediated by the induction of Treg cells. 7, 14, [40] [41] [42] [43] [44] pDCs play a crucial role in the induction and maintenance of respiratory and oral tolerance, 7, 43 and it has been shown that activation of pDCs induces Treg cells. 40, 42 Recently, we identified a novel CD8a 1 pDC subset that is more efficient than conventional pDCs in inducing forkhead box protein 3
1 Treg cells. 14 However, our current findings provide the first evidence that activated pDCs can directly suppress ILC2 function and homeostasis. Several models, such as Siglec-H-DTR, are available to deplete pDCs; however, we selected BDCD-2-DTR in our experiments because it has been shown that administration of DT to BDCD-2-DTR mice leads to efficient and selective depletion of pDCs. 27 However, DT administration to Siglec-H-DTR mice leads to depletion of non-pDC cells, including marginal zone macrophages and conventional dendritic cell precursors. 45 Although we show that activation of pDCs can offer a powerful tool to regulate the function and homeostasis of ILC2s, viral infections can contribute to both asthma inception and exacerbation through different mechanisms that involve adaptive immunity, as well as innate/innate-like immune cells, including pDCs and natural killer T cells. 46, 47 In fact, it has been shown that influenza infection, for instance, can cause IL-33 production by alveolar macrophages and lung epithelial cells, which in turn activate ILC2s and invariant natural killer T cells causing AHR and airway inflammation. 46 Activation of pDCs in such viral respiratory tract infections can regulate ILC2s and invariant natural killer T cells directly and through induction of Treg cells, respectively. Further studies are needed to identify whether pDCs can play the dual role of actively eliciting antiviral immunity and directly regulating lung inflammation and AHR.
In conclusion, we show that R848-activated pDCs reduce AHR, a cardinal and most clinically relevant feature of asthma, and decrease lung inflammation in an IFN-a-dependent manner. Activated pDCs can regulate both cytokine production and homeostasis of ILC2s through IFN-a production. Our findings shed a new light on the underlying mechanisms of regulation of ILC2s and ILC2-mediated asthma pathogenesis. Moreover, our findings have clear clinical implications in asthma control and management. , and BDCA-2-DTR mice were purchased from the Jackson Laboratory and bred in our animal facility at the University of Southern California. Ifnar 2/2 and C57BL/6J mice were purchased from the Jackson Laboratory and used directly in our experiments. We used 5-to 8-week-old age-matched female mice in our studies. All the described studies were approved by the Institutional Animal Care and Use Committee of the University of Southern California or Janssen Research & Development.
In the experiments described in Figs 1-5 , we administrated the indicated dose of R848 (InvivoGen) and A alternata (Greer Laboratories) intranasally after achievement of general anesthesia (ketamine [50 mg/kg body weight] plus xylazine [5 mg/kg body weight]). In the experiments described in Fig 1 , DTwas administered intraperitoneally in conscious mice. Lung function was evaluated by means of direct measurement of airway resistance and dynamic compliance to increasing doses of methacholine in restrained, tracheostomized, mechanically ventilated mice through the FinePointe RC system (Data Sciences International, St Paul, Minn) after achievement of general anesthesia, as described previously.
E1,E2
For experiments described in Fig 1, we administered either DT (100 ng per mouse administered intraperitoneally; EMD Millipore, Billerica, Mass) or PBS on day zero.
Collection of BAL fluid and lung histology
BAL was performed after evaluation of lung function in euthanized mice, as we described previously.
E1, E3 In brief, we tracheostomized and intubated the mice and then washed the airways 3 times with 1 mL of PBS each time, followed by centrifuging at 400g for 7 minutes and harvesting the cells. After taking BAL fluid, we took lung samples, fixed them in paraformaldehyde 4%, and created lung histology slides, as described previously. E4 Images of hematoxylin and eosin-stained tissue slides were acquired with a KeyenceBZ-9000 microscope (Keyence). Histologic images were analyzed with the BZ-II Image Analysis Application (Keyence).
Flow cytometric antibodies and reagents
Statistical analysis
We repeated each experiment at least 2 times (n 5 3-5 mice per group in each experiment), and data are representative of at least 2 independent experiments. Lung function data were analyzed by using repeated measurements with the general linear model. For comparing 2 groups, we used the Student t test confirmed by using a Mann-Whitney U test. For multigroup comparisons, we used 1-way ANOVA with Bonferroni post hoc test. Data were analyzed with GraphPad Prism software (GraphPad Software). A P value of .05 or less was considered statistically significant. by means of flow cytometry after intracellular staining. Data are shown as means 6 SEMs (n 5 2-5 each). *P < .05, **P < .01, and ***P < .005.
